Clinical Trial Update: Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE [Phase 3]

View source ↗

Summary

Phase 3 trial update for HDL-raising therapy using niacin with laropiprant; results posted in 2014 showed no reduction in major vascular events and raised safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Coronary Artery Disease
• Diabetes Mellitus
• Peripheral Arterial Disease

Drugs mentioned

• Laropiprant (laropiprant)
• Niaspan (niacin (nicotinic acid))

Snippet

Sponsor: University of Oxford | Conditions: Cardiovascular Disease, Peripheral Arterial Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-01-28